Clinical trial • Phase III • Gastroenterology|Nephrology

ARGIPRESSIN for Liver transplantation | Acute kidney injury

Phase III trial of ARGIPRESSIN for Liver transplantation | Acute kidney injury.

Overview

Trial Therapeutic Area
Gastroenterology|Nephrology
Trial Disease
Liver transplantation | Acute kidney injury
Trial Stage
Phase III
Drug Modality
Peptide/protein/enzyme|Small molecule

Key dates

Initial CTIS Submission Date
02-10-2023
First CTIS Authorization Date
12-01-2024

Trial design

REVERPLEG 40 U.I./2 mL (argipressin) solution for infusion; max daily dose 86.4 U (route: intravenous). Comparator: NORADRENALINE VIATRIS 2 mg/ml (noradrenaline tartrate) solution for infusion; max daily dose 40 mg (route: intravenous).-controlled Phase III trial in France.

Comparator
REVERPLEG 40 U.I./2 mL (argipressin) solution for infusion; max daily dose 86.4 U (route: intravenous). Comparator: NORADRENALINE VIATRIS 2 mg/ml (noradrenaline tartrate) solution for infusion; max daily dose 40 mg (route: intravenous).
Target Sample Size
304

Eligibility

Recruits 304 Vulnerable population not selected. Adults under guardianship or trusteeship and persons deprived of their liberty are explicitly excluded. Patients unable to give informed consent (language barrier) are excluded. All participants must receive clear information and give signed informed consent; subject information and consent documents for adults (L1_SIS and ICF adults, simplified SIS for patients awaiting transplants) are listed..

Pregnancy Exclusion
Pregnancy or breastfeeding
Vulnerable Population
Vulnerable population not selected. Adults under guardianship or trusteeship and persons deprived of their liberty are explicitly excluded. Patients unable to give informed consent (language barrier) are excluded. All participants must receive clear information and give signed informed consent; subject information and consent documents for adults (L1_SIS and ICF adults, simplified SIS for patients awaiting transplants) are listed.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 18 years"}
  • {"criterion_text":"- Any adult patient with a scheduled liver transplantation"}
  • {"criterion_text":"- All participants will need to be given clear information about the study and give signed informed consent"}
  • {"criterion_text":"- Person affiliated to the Social Security"}

Exclusion criteria

  • {"criterion_text":"- Super-emergency for liver transplantation or fulminant hepatitis"}
  • {"criterion_text":"- Pregnancy or breastfeeding"}
  • {"criterion_text":"- Patient listed for or receiving simultaneous liver-kidney transplantation (SLKT)"}
  • {"criterion_text":"- Patients with end-stage renal disease (chronic eGFR < 15 mL/min/1.73 m2 or requiring extra-renal purification before liver transplantation"}
  • {"criterion_text":"- Patient with epilepsy"}
  • {"criterion_text":"- Hypersensitivity to arginine-vasopressin and to its excipients"}
  • {"criterion_text":"- Patient refusal"}
  • {"criterion_text":"- Patients for whom it is impossible to give informed consent (language barrier)"}
  • {"criterion_text":"- Adults under guardianship or trusteeship, persons deprived of their liberty"}
  • {"criterion_text":"- Patient enrolled in another interventional clinical study"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- Stages of AKI according to AKI Network criteria (KDIGO score) during the first 7 postoperative days","definition_or_measurement_approach":"Measured as stages of acute kidney injury using AKI Network criteria (KDIGO score) during the first 7 postoperative days."}

Secondary endpoints

  • {"endpoint_text":"- The number of packed red blood cells and fresh frozen plasma transfused intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as count/units of packed red blood cells and fresh frozen plasma transfused intraoperatively and during the first 12 postoperative hours."}
  • {"endpoint_text":"- The need for renal replacement for replacement therapy (RRT) in ICU","definition_or_measurement_approach":"Recorded need for renal replacement therapy (RRT) in intensive care unit."}
  • {"endpoint_text":"- Average intraoperative norepinephrine concentrations","definition_or_measurement_approach":"Measured as average intraoperative concentrations of norepinephrine."}
  • {"endpoint_text":"- Average intraoperative concentrations of other vasopressors and inotropes (Adrenalin, Dobutamine)","definition_or_measurement_approach":"Measured as average intraoperative concentrations of other vasopressors and inotropes (e.g., adrenaline, dobutamine)."}
  • {"endpoint_text":"- Number of platelets transfused intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as count/units of platelets transfused intraoperatively and during the first 12 postoperative hours."}
  • {"endpoint_text":"- Amount of vascular filling solutions intraoperatively and during the first 12 hours postoperatively","definition_or_measurement_approach":"Measured as volume/amount of vascular filling solutions administered intraoperatively and during the first 12 postoperative hours."}
  • {"endpoint_text":"- Sequential Organ Failure Assessment (score SOFA) on the third postoperative day","definition_or_measurement_approach":"Measured using the Sequential Organ Failure Assessment (SOFA) score on the third postoperative day."}
  • {"endpoint_text":"- Number of days alive outside intensive care unit during the 30 day post-operation","definition_or_measurement_approach":"Measured as number of days alive and not in intensive care during the 30 days following operation."}
  • {"endpoint_text":"- Mortality at 30 days","definition_or_measurement_approach":"All-cause mortality measured at 30 days post-operation."}

Recruitment

Planned Sample Size
304
Recruitment Window Months
25
Consent Approach
Adults must receive clear information and provide signed informed consent. Consent documents available for publication include L1_SIS-simplified for patients awaiting transplants and L1_SIS and ICF adults; documents and public materials are in French. Minors are excluded, so no assent procedures are described. Patients unable to give informed consent (language barrier) are excluded.

Geography

Total Number Of Sites
9
Total Number Of Participants
304

France

Earliest CTIS Part Ii Submission Date
22-12-2023
Latest Decision Or Authorization Date
19-12-2025
Processing Time Days
728
Number Of Sites
9
Number Of Participants
304

Sites

Site Name
Assistance Publique Hopitaux De Paris
Department Name
Anesthésie-Réanimation
Contact Person Name
Daniel EYRAUD
Contact Person Email
daniel.eyraud@aphp.fr
Site Name
Hospices Civils De Lyon
Department Name
Anesthésie-Réanimation
Contact Person Name
Thomas SCHULZ
Contact Person Email
thomas.schulz@chu-lyon.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Anesthésie-Réanimation
Contact Person Name
Antoine DEWITTE
Site Name
Centre Hospitalier Regional Universitaire De Tours
Department Name
Anesthésie-Réanimation
Contact Person Name
Eric LEVESQUE
Contact Person Email
e.levesque@chu-tours.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Anesthésie-Réanimation
Contact Person Name
Emmanuel WEISS
Contact Person Email
emmanuel.weiss@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Anesthésie-Réanimation
Contact Person Name
Jacques DURANTEAU
Contact Person Email
jacques.duranteau@aphp.fr
Site Name
University Hospital Of Clermont-Ferrand
Department Name
Anesthésie-Réanimation
Contact Person Name
Thomas GODET
Contact Person Email
tgodet@chu-clermontferrand.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Anesthésie-Réanimation
Contact Person Name
Gilles LEBUFFE
Contact Person Email
gilles.lebuffe@chru-lille.fr
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Anesthésie-Réanimation
Contact Person Name
Baptiste LORDIER

Sponsor

Primary sponsor

Full Name
Assistance Publique Hopitaux De Paris
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
REVERPLEG 40 U.I./2 mL, solution à diluer pour perfusion
Active Substance
ARGIPRESSIN
Modality
Peptide/protein/enzyme
Routes Of Administration
INTRAVENOUS
Route
INTRAVENOUS
Authorisation Status
Authorised
Maximum Dose
86.4 U unit(s)
Investigational Product Name
NORADRENALINE VIATRIS 2 mg/ml SANS SULFITES, solution à diluer pour perfusion
Active Substance
NORADRENALINE TARTRATE
Modality
Small molecule
Routes Of Administration
INTRAVENOUS
Route
INTRAVENOUS
Authorisation Status
Authorised
Maximum Dose
40 mg milligram(s)

Related trials

Other published trials that may interest you.